Advertisement

Organisation › Details
Ethris GmbH
Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, we are a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formulation and nebulization technologies. We are rapidly advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients’ lives. *
![]() |
Start | 2009-12-31 established |
![]() |
Industry | SNIM®RNA technology |
Industry 2 | ETH47 (Ethris) | |
![]() |
Person | Rudolph, Carsten (Ethris 201301 Managing Director + Co-Founder) |
Person 2 | Planck, Christian (Ethris 201301 Managing Director + Co-founder) | |
![]() |
Region | Martinsried |
Country | Germany | |
Street | 3 Semmelweisstr. | |
City | 82152 Planegg | |
Tel | +49-89-8955788-0 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2013-01-07) |
* Document for »About Section«: Ethris GmbH. (2/1/22). "Press Release: Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases". Munich. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Ethris GmbH
- [1] Ethris GmbH. (6/18/24). "Press Release: Cipla EU to Invest an Additional EUR 3 Million in Ethris". Mumbai & Munich....
- [2] Ethris GmbH. (6/18/24). "Press Release: Ethris Announces $5 Million in Funding to Prepare Lead Candidate ETH47 for Phase 2 Stud". Munich....
- [3] Ethris GmbH. (12/29/22). "Press Release: Cipla EU to Invest EUR 15 million in Ethris, Initiating a Strategic Collaboration". Mumbai & Munich....
- [4] Ethris GmbH. (12/21/22). "Press Release: Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses". Munich....
- [5] Ethris GmbH. (2/1/22). "Press Release: Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases". Munich....
- [6] Neurimmune AG. (4/1/20). "Press Release: Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of Covid-19". Zurich & Munich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top